Insulin aspart
- Generic Name
- Insulin aspart
- Brand Names
- Fiasp, Novolog, Novolog Mix, Novomix, Novorapid, Novorapid Penfill, Ryzodeg, Truvelog Mix 30, Kirsty (previously Kixelle), NovoRapid, Insulin aspart Sanofi, NovoMix
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 116094-23-6
- Unique Ingredient Identifier
- D933668QVX
- Background
Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin ...
- Indication
Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Diabetic Ketoacidosis, Gestational Diabetes Mellitus (GDM), Hyperglycemia during critical illness
- Associated Therapies
- -
Observational Study to Evaluate the Effectiveness and Safety of Levemir®, NovoMix® 30 and NovoRapid® in Insulin naïve Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2008-10-13
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 10408
- Registration Number
- NCT00771680
- Locations
- 🇺🇦
Novo Nordisk Investigational Site, Kiev, Ukraine
Long Term Safety Trial to Compare Insulin Treatment With Preprandial Inhaled Human Insulin to s.c. Insulin Aspart Both Combined With NPH in Subjects With Type 1 Diabetes
- Conditions
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 305
- Registration Number
- NCT00725036
- Locations
- 🇦🇺
Novo Nordisk Investigational Site, Stones Corner, Australia
Observational Study to Evaluate Safety and Efficacy of Insulin Therapy in Type 2 Diabetes Mellitus Subjects Failing on Oral Anti-diabetic Agents
- First Posted Date
- 2008-07-15
- Last Posted Date
- 2016-11-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1667
- Registration Number
- NCT00715780
- Locations
- 🇮🇩
Novo Nordisk Investigational Site, Jakarta, Indonesia
An Observational Study to Assess Safety and Effectiveness of Intravenous NovoRapid® in Hospitalised Subjects
- Conditions
- Interventions
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3024
- Registration Number
- NCT00700648
- Locations
- 🇮🇳
Novo Nordisk Investigational Site, Bangalore, India
An Observational Study of Efficacy and Safety of Modern Insulin in Diabetes Patients Switched From Anti-diabetic Treatment
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 5926
- Registration Number
- NCT00698269
- Locations
- 🇸🇦
Novo Nordisk Investigational Site, Riyadh, Saudi Arabia
Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin
- Conditions
- Interventions
- First Posted Date
- 2008-05-13
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3809
- Registration Number
- NCT00676741
- Locations
- 🇸🇰
Novo Nordisk Investigational Site, Bratislava, Slovakia
Comparison of the Pharmacodynamics and Pharmacokinetics of Insulin Aspart and Human Insulin in Elderly People With Type 2 Diabetes
- Conditions
- First Posted Date
- 2008-05-13
- Last Posted Date
- 2017-03-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 19
- Registration Number
- NCT00676819
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Köln, Germany
Observational Study to Assess the Efficacy and Safety of NovoRapid™ Flexpen™
- Conditions
- Interventions
- First Posted Date
- 2008-05-09
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 373
- Registration Number
- NCT00675220
- Locations
- 🇵🇭
Novo Nordisk Investigational Site, Manilla, Philippines
Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin
- Conditions
- Interventions
- First Posted Date
- 2008-05-02
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 6500
- Registration Number
- NCT00670722
- Locations
- 🇨🇿
Novo Nordisk Investigational Site, Prague, Czech Republic
Management of Hyperglycemia in the ER: A Randomized Clinical Trial of a Subcutaneous Insulin Aspart Protocol Coupled With Rapid Initiation of Basal Bolus Insulin Prior to Hospital Admission Versus Usual Care
- Conditions
- Interventions
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2013-11-21
- Lead Sponsor
- Emory University
- Registration Number
- NCT00663624
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.